{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959902",
  "id": "02959902",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0832",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwrlpwdpmwt3.pdf",
  "summary": "### Key Material Information:  \n Lean and highly relevant summary :  \n\n- **Clinical Trial Update**: Second confirmed **complete response (CR)** recorded in the ACCENT trial evaluating **narmafotinib (AMP945)** + chemotherapy in advanced pancreatic cancer.  \n- **Significance**: CRs are **extremely rare** in advanced pancreatic cancer (only 1 in 431 patients in prior seminal study). Pathological CR also reported earlier (ASX: 16 Jun 2025).  \n- **Trial Details**: Phase 1b/2a single-arm study (55 patients) across Australia/South Korea; primary endpoints include **Objective Response Rate (ORR)** and **Duration on Trial (DOT)**.  \n\n**Impact**: Positive clinical data may influence **valuation** and **partnering potential**. No capital/financial updates.  \n\n*Omitted: Background on FAK, operational details, contact info.*",
  "usage": {
    "prompt_tokens": 1271,
    "completion_tokens": 189,
    "total_tokens": 1460,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T22:47:06.596385"
}